Unknown

Dataset Information

0

Chemotherapeutic efficacy of phosphodiesterase inhibitors in chagasic cardiomyopathy.


ABSTRACT:

Background

Chagasic cardiomyopathy (CCM) caused by Trypanosoma cruzi (Tc) infection is prevalent in Latin America and recognized as an emerging infectious heart disease in the US. The NO-cGMP-PKG1α pathway maintains cardiac homeostasis and inotropy and may be disturbed due to phosphodiesterase (PDE5) mediated cGMP catabolism in CCM.

Methods and results

C57BL/6 mice were infected with Tc, and at the end of acute parasitemia (i.e. 45 days post-infection), treated with sildenafil (SIL, 1 mg/kg) twice per week for 3 weeks. Mice were monitored at 150 days post-infection corresponding to chronic disease phase. The cGMP/PKG activity was decreased by 2-fold and PDE5 expression was increased by 1.4-fold and 100% at RNA and protein levels, respectively, in chagasic myocardium. Transthoracic echocardiography showed the left ventricular (LV) systolic function, i.e., stroke volume, cardiac output, and ejection fraction, were significantly decreased in chagasic mice. Sildenafil treatment resulted in normal levels of PDE5 and cGMP/PKG activity and preserved the LV function in chagasic mice. The cardioprotective effects of SIL were provided through inhibition of cardiac collagenosis and chronic inflammation that otherwise were pronounced in CCM. Further, mtDNA-encoded gene expression and ADP-coupled mitochondrial respiration were decreased and mitochondrial oxidative stress and cellular oxidative damage (lipid hydroperoxides and protein carbonyls) were increased in chagasic myocardium. SIL treatment restored the mtDNA-encoded gene expression and complex I (but not complex II) dependent ADP-coupled respiration, and established the oxidant/antioxidant balance in chagasic myocardium. In vitro studies in cardiomyocytes verified that SIL conserved the redox metabolic state and cellular health via maintaining the antioxidant status that otherwise was compromised in response to Tc infection.

Conclusion

SIL therapy was useful in controlling the LV dysfunction and chronic pathology in CCM.

SUBMITTER: Wen JJ 

PROVIDER: S-EPMC5065248 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC9010479 | biostudies-literature
| S-EPMC8592338 | biostudies-literature
| S-EPMC5215570 | biostudies-literature
| S-EPMC7408395 | biostudies-literature
| S-EPMC4648062 | biostudies-literature
| S-EPMC6147028 | biostudies-literature
| S-EPMC2922320 | biostudies-other
| S-EPMC5563592 | biostudies-literature
| S-EPMC9708147 | biostudies-literature
| S-EPMC4977507 | biostudies-literature